Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer

Journal of Clinical Investigation

Volumn 115, Issue 6, 2005, Pages 1503-1521

  Glinsky, Gennadi V ^a   Berezovska, Olga ^a   Glinskii, Anna B ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER; CANCER RECURRENCE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENETIC MARKER; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMAN VERSUS ANIMAL COMPARISON; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MESOTHELIOMA; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; STEM CELL; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELLS;

EID: 20444457518     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI23412     Document Type: Article

References (66)

1. Lessard, J., and Sauvageau, G. 2003. BMI-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 423:255-260.
2. Park, I.-K., et al. 2003. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 423:302-305.
3. Molofsky, A.V., et al. 2003. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature. 425:962-967.
4. Dick, J.E. 2003. Self-renewal writ in blood. Nature. 423:231-233.
5. Pardal, R., Clarke, M.F., and Morrison, S.J. 2003. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer. 3:895-902.
6. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke, M.F. 2003. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 100:3983-3988.
7. Smalley, M., and Ashworth, A. 2003. Stem cells and breast cancer: a field in transit. Nat. Rev. Cancer. 3:832-844.
8. Lessard, J., Baban, S., and Sauvageau, G. 1998. Stage-specific expression of polycomb group genes in human bone marrow cells. Blood. 91:1216-1224.
9. Haupt, Y., Bath, M.I., Harris, A.W., and Adams, J.M. 1993. BMI-1 transgene induces lymphomas and collaborates with Myc in tumorigenesis. Oncogene. 8:3161-3164.
10. Alkema, M.J., Jacobs, H., van Lohuizen, M., and Berns, A. 1997. Perturbation of B and T cell development and predisposition to lymphomagenesis in Eμ-Bmi-1 transgenic mice require the Bmi-1 RING finger. Oncogene. 15:899-910.
11. Vonlanthen, S., et al. 2001. The Bmi-1 oncoprotein is differentially expressed in non-small-cell lung cancer and correlates with INK4A-ARF locus expression. Br. J. Cancer. 84:1372-1376.
12. Dimri, G.P., et al. 2002. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 62:4736-4745.
13. LaTulippe, E., et al. 2002. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62:4499-4506.
14. Singh, D., et al. 2002. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 1:203-209.
15. Glinsky, G.V., Glinskii, A.B., Stephenson, A.J., Hoffmann, R.M., and Gerald, W.L. 2004. Expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 113:913-923. doi:10.1172/JCI200420032.
16. Glinsky, G.V., Krones-Herzig, A., Glinskii, A.B., and Gebauer, G. 2003. Microarray analysis of xenograft-derived cancer cell lines representing multiple experimental models of human prostate cancer. Mol. Carcinog. 37:209-221.
17. Magee, J.A., et al. 2001. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 61:5692-5696.
18. Dhanasekaran, S.M., et al. 2001. Delineation of prognostic biomarkers in prostate cancer. Nature. 412:822-826.
19. Welsh, J. B., et al. 2001. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 61:5974-5978.
20. Luo, J., et al. 2001. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res. 61:4683-4688.
21. Stamey, T.A., et al. 2001. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J. Urol. 166:2171-2177.
22. Luo, J., et al. 2002. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate. 51:189-200.
23. Rhodes, D.R., Barrette, T.R., Rubin, M.A., Ghosh, D., and Chinnaiyan, A.M. 2002. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathways dysregulation in prostate cancer. Cancer Res. 62:4427-4433.
24. Varambally, S., et al. 2002. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 419:624-629.
25. Henshall, S.M., et al. 2002. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 63:4196-4203.
26. Lapointe, J., et al. 2004. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 101:811-816.
27. Stuart, R.O., et al. 2004. In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc Natl. Acad. Sci. U. S. A. 101:615-620.
28. Huang, E., et al. 2003. Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat. Genet. 34:226-230.
29. Lamb, J., et al. 2003. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 114:323-334.
30. Chang, H.Y., et al. 2004. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2:1-9.
31. Raaphorst, F.M., et al. 2003. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia. 5:481-488.
32. Gingrich, J.R., et al. 1996. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 56:4096-4102.
33. van 't Veer, L.J., et al. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:530-536.
34. Bhattacharjee, A., et al. 2001. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. U. S. A. 98:13790-13795.
35. van Kemenade, F.J., et al. 2001. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 97:3896-3901.
36. Hemmati, H.D., et al. 2003. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. U. S. A. 100:15178-15183.
37. Leung, C., et al. 2004. BMI1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature. 428:337-341.
38. Ramaswamy, S., Ross, K.N., Lander, E.S., and Golub, T.R. 2003. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33:49-54.
39. van de Vijver, M.J., et al. 2002. A gene expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:1999-2009.
40. Bernards, R., and Weinberg, R.A. 2002. A progression puzzle. Nature. 418:823.
41. Wang, X., et al. 2003. Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature. 422:897-901.
42. Vassilopoulos, G., Wang, P.-R., and Russell, D.W. 2003. Transplanted bone marrow regenerates liver by cell fusion. Nature. 422:901-904.
43. Alvarez-Dolado, M., et al. 2003. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature. 425:968-973.
44. Weimann, J.M., Johansson, C.B., Trejo, A., and Blau, H.M. 2003. Stable reprogrammed heterokaryons form spontaneously in Purkinje neurons after bone marrow transplant. Nat. Cell Biol. 5:959-966.
45. Aboody, K.S., et al. 2000. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl. Acad. Sci. U. S. A. 97:12846-12851.
46. Brown, A.B., et al. 2003. Intravascular delivery of neural seem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum. Gene Ther. 14:1777-1785.
47. Willenbring, H., et al. 2004. Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. Nat. Med. 10:744-748.
48. Rhodes, D.R., et al. 2004. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc. Natl. Acad. Sci. U. S. A. 101:9309-9314.
49. Shaffer, A.I., et al. 2001. Signatures of the immune response. Immunity. 15:375-385.
50. Hernando, E., et al. 2004. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature. 430:797-802.
51. Johnson, V.L., Scott, M.I., Holt, S.V., Hussein, D., and Taylor, S.S. 2004. Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression. J. Cell Sci. 117:1577-1589.
52. Martin-Lluesma, S., Stucke, V.M., and Nigg, E.A. 2002. Role of Hec1 in spindle checkpoint signalling and kinetochore recruitment of Mad1/Mad2. Science. 297:2267-2270.
53. Baron, V., et al. 2003. Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo. Oncogene. 22:4194-4204.
54. Tavazoie, S., Hughes, J.D., Campbell, M.J., Cho, R.J., and Church, G.M. 1999. Systematic determination of genetic network architecrure. Nat. Genet. 22:281-285.
55. Su, A.I., et al. 2002. Large-scale analysis of the human and mouse transcriptomes. Proc. Natl. Acad. Sci. U. S. A. 99:4465-4470.
56. Beer, D.G., et al. 2002. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8:816-824.
57. Lu, K.H., et al. 2004. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 10:3291-3300.
58. Lancaster, J.M., et al. 2004. Gene expression patterns that characterize advanced stage serous ovarian cancers. J. Soc. Gynecol. Investig. 11:51-59.
59. Dyrskjot, L., et al. 2003. Identifying distinct classes of bladder carcinoma using microarrays. Nat. Genet. 33:90-96.
60. Shipp, M.A., et al. 2002. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 8:68-74.
61. Rosenwald, A., et al. 2002. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:1937-1947.
62. Rosenwald, A., et al. 2003. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 3:185-197.
63. Gordon, G.J., et al. 2003. Using gene expression ratios to predict outcome among patients with mesothelioma. J. Natl. Cancer Inst. 95:598-605.
64. Pomeroy, S.L., et al. 2002. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 415:436-442.
65. Nutt, C.L., et al. 2003. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 63:1602-1607.
66. Bullinger, L., et al. 2004. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350:1605-1616.